Pfizer Rating: Buy — Performance in December quarter was weak

By: |
February 24, 2020 3:15 AM

Though prospects are good, FY20-22e EPS down 3-5% with TP reduced to Rs 4,961

Pfizer Rating, Pfizer Q3FY20 performance, AIOCD data, Ebitda, CAGR, S,G&A expensesRevenue growth of 4.7% was sharply lower than the AIOCD reported growth of 18.9%.

Pfizer’s (PFL’s) Q3FY20 performance was weak during the quarter. Revenue grew at a tepid 4.7% y-o-y to Rs 5.4 bn. Ebitda margin declined 520bps y-o-y and 420bps q-o-q to 24.8% (lowest in several quarters). Adjusted PAT grew 5.4% y-o-y to Rs 1.4 bn. As per AIOCD data, growth for the company stood at 18.9%. The lower primary growth would suggest some level of channel destocking which we believe would normalise in the coming quarters. We remain positive on the company’s growth visibility with exposure only in domestic formulations, strong balance sheet with deep cash reserves, new power brands and strong brand equity built over the years. Maintain Buy.

Muted operational performance: Revenue growth of 4.7% was sharply lower than the AIOCD reported growth of 18.9%. We believe it could be due to some level of channel destocking. Also the company has divested rights and interests in two brands and recognised a net gain of Rs 250 mn in other income. This divestment could also have caused a lower revenue recognition during the quarter. A sharp rise of 15.1% y-o-y and 6.3% q-o-q in the S,G&A expenses coupled with lower gross margin negatively affected the Ebitda (-13.5% y-o-y, -18.7% q-o-q).

Outlook: We expect revenue to grow 9.2% over FY19-FY22e. Operating leverage would drive margin improvement of 280bps and result in 18.2% earnings CAGR over FY19-FY22e. This would help generate healthy free cashflows of ~Rs 22 bn over FY20e-FY22e. The RoIC profile is very strong at 30.5% in FY19 and we expect it to increase to 50.4% by FY22e.

Valuations: We revise our rev/earnings estimates for FY20e-FY22e by 1-2%/3-5% reflecting the weak showing. Maintain Buy with a revised TP of Rs 4,961 based on 32xFY22e EPS (earlier: Rs 5,239).

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Route Mobile share price surges 6.74% on investment from Goldman Sachs; zooms 98% from IPO price
2IPO Watch: CAMS, Chemcon oversubscribed, Angel Broking going strong but grey market premiums slip
3CAMS IPO fully subscribed on day two, retail investor portion subscribed 1.79 times so far